Carl L Gordon bought $20.0M of Electra Therapeutics (ETRA)
Executed Sep 21, disclosed Sep 23, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Sep 23), the stock returned -33.3% (delay-adjusted); from the execution session (Sep 21), -38.2%. Derived: entry at the session's open, exit at the close 20 sessions later.
Carl L Gordon (Director) filed 6 Form 4 reports in the trailing twelve months (6 purchases, 0 sales), most often in Electra Therapeutics, Inc. (ETRA). Across 4 priced purchase filings, the average 21-session return was +17.0% from execution and +14.9% from disclosure (delay-adjusted; derived). The largest single filing was $20.0M of ETRA (1,333,333 sh across 2 lots, as filed), executed Sep 21.
Healthcare · Electra Therapeutics, Inc. is a clinical-stage biotechnology company
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→76,300 sh across 3 lots
Exec Nov 6
Filed Nov 10 · 8:14 PM ET ETRAPURCHASE Electra Therapeutics, Inc. $3.5M
458,304 sh across 8 lots
Exec Nov 3
Filed Nov 5 · 5:47 PM ET